Breast cancer Immunotherapy

#Breast #cancer is one of the most commonly diagnosed cancer types among women globally. Globally, there were an estimated 2.1 million new cases of breast cancer and 630,000 deaths due to breast cancer in 2018. #Immunotherapy for #breast_cancer is developing rapidly as new studies demonstrate improved outcomes in subsets of breast cancer. Approximately 1 in 8 women and about 1 in 1,000 men will develop invasive breast cancer at some point in their lives. Thus, the need for effective, lasting breast cancer treatment is urgent.

Increased risk for breast cancer is associated with a personal or family history of the #disease and inherited #genetic #mutations in breast cancer susceptibility #genes. These include #BRCA1 and #BRCA2 and other less common inherited gene mutations. An inherited predisposition to develop breast cancer accounts for approximately 5%-10% of all breast cancer cases, but is rare in the general population in less than 1%. Women with BRCA1 and BRCA2 mutations have an estimated 45% to 65% higher risk of developing breast cancer by age 70, though the risk is highest around age 40. People with these mutations should discuss their risk with a genetic counsellor. Other known risk factors include #obesity, use of MHT (a hormone therapy that combines #progestin and #estrogen), high breast tissue density, alcohol consumption, and physical inactivity.

One challenge of #immunotherapy is that it can cause substantial side effects, including life-threatening ones. The most common immunotherapy side effects are #skin_reactions, such as redness and blistering, and flu-like symptoms, such as #fever, nausea, #weakness, and body aches. Different types of immunotherapy can cause different side effects. Another challenge is the high cost of this treatment.

For more details please follow the link: https://frontiersmeetings.com/conferences/breastcancercongress/

For queries and details contact us: breastcancer@globalbreastcancercongress.org